Anne-Sophie Michallet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anne-Sophie Michallet has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Gilles Salles
Memorial Sloan Kettering Cancer Center, New York, NY
5 shared publications Bertrand Coiffier
Department of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
4 shared publications- Bertrand Coiffier
Department of Hematology, Hospices Civils de Lyon, Lyon, France
3 shared publications Fadhela Bouafia-Sauvy
Department of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
3 shared publicationsLaure Lebras
Department of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
3 shared publicationsBruno Cazin
Department of Hematology, Huriez university hospital, Lille, France
2 shared publications
Latest Publications
- Open Access
- 3 April 2015
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 100 (7) , e269-e271
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma
- 3 April 2015
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 100 (7) , e269-e271
Open AccessSequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma
- 28 January 2014
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (8) , 1939-1941
Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management
- 28 January 2014
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (8) , 1939-1941
Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management
- 30 April 2013
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 4 (2) , 141-147
First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis
- 30 April 2013
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 4 (2) , 141-147
First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis
- 30 April 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (12) , 2738-2741
Pregnancy and multiple myeloma are not antinomic
- 30 April 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (12) , 2738-2741
Pregnancy and multiple myeloma are not antinomic
- Open Access
- 8 June 2012
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 27
Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma
Background: Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease. Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors.Methods: Thirty-six adult patients with nasal-type NK/T-cell lymphoma were recruited and assessed. In total, 80 % of patients were classified as having upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and 20 % extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL).Results: For advanced-stage disease, chemotherapy alone (CT) was the primary treatment (84 %vs.10 % for combined CT + radiation therapy (RT), respectively), while for early-stage disease, 50 % of patients received the combination of CT + RT and 50 % CT alone. Five-year overall survival (OS) and progression-free survival (PFS) rates were 39 % and 33 %. Complete remission (CR) rates were significantly higher when using CT + RT (90 %)versusCT alone (33 %) (p < 0.0001). For early-stage disease, CR rates were 37 % for CT aloneversus100 % for CT + RT. Quality of response was significantly associated with survival, with 5-year OS being 80 % for CR patientsversus0 % for progressive disease patients (p < 0.01).Conclusion: Early RT concomitantly or sequentially with CT led to improved patient outcomes, with quality of initial response being the most important prognosticator for 5-year OS.
- 8 June 2012
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 27
Open AccessComplete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma
Background: Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease. Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors.Methods: Thirty-six adult patients with nasal-type NK/T-cell lymphoma were recruited and assessed. In total, 80 % of patients were classified as having upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and 20 % extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL).Results: For advanced-stage disease, chemotherapy alone (CT) was the primary treatment (84 %vs.10 % for combined CT + radiation therapy (RT), respectively), while for early-stage disease, 50 % of patients received the combination of CT + RT and 50 % CT alone. Five-year overall survival (OS) and progression-free survival (PFS) rates were 39 % and 33 %. Complete remission (CR) rates were significantly higher when using CT + RT (90 %)versusCT alone (33 %) (p < 0.0001). For early-stage disease, CR rates were 37 % for CT aloneversus100 % for CT + RT. Quality of response was significantly associated with survival, with 5-year OS being 80 % for CR patientsversus0 % for progressive disease patients (p < 0.01).Conclusion: Early RT concomitantly or sequentially with CT led to improved patient outcomes, with quality of initial response being the most important prognosticator for 5-year OS.
- 16 March 2012
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (8) , 1633-1637
Sequential combination of high dose methotrexate andl-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm
(2012). Sequential combination of high dose methotrexate and l-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leukemia & Lymphoma: Vol. 53, No. 8, pp. 1633-1637.
- 16 March 2012
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (8) , 1633-1637
Sequential combination of high dose methotrexate andl-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm
(2012). Sequential combination of high dose methotrexate and l-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leukemia & Lymphoma: Vol. 53, No. 8, pp. 1633-1637.
- 1 September 2011
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 23 (5) , 449-454
Maintenance therapy in follicular lymphoma
This article reviews the potential benefit of maintenance therapy for patients with follicular lymphoma. Follicular lymphoma, despite substantial improvements in survival, is usually incurable. Several randomized studies have shown that the combination of anti-CD20 and chemotherapy can improve overall survival for these patients. Recently, the old concept of maintenance treatment developed for acute leukemias was reintroduced in the treatment of indolent lymphomas. On the basis of its favorable toxicity profile, single agent rituximab remains a valuable option when given in a prolonged schedule to obtain durable remissions. A first remission is easily obtained but relapses appear unavoidable. Patients achieving a partial response have poorer outcomes compared with those achieving complete remission. Furthermore, it has been demonstrated that among patients with follicular lymphoma who reach complete remission, those obtaining negative minimal residual disease, as assessed by molecular biology, have a better outcome compared with those remaining with residual disease. There is, therefore, a rationale to give additional treatment in an attempt to eradicate or to control the lymphoma cells responsible for relapse. An ideal maintenance regimen would have limited toxicity and should be easy to administer. Results of the International Primary Rituximab and Maintenance study show that 2 years of rituximab maintenance prolongs progression free survival, delays the time to next antilymphoma treatment and improves the quality of response in patients with previously untreated follicular lymphoma. Rituximab maintenance was well tolerated with a limited number of adverse events.
- 1 September 2011
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 23 (5) , 449-454
Maintenance therapy in follicular lymphoma
This article reviews the potential benefit of maintenance therapy for patients with follicular lymphoma. Follicular lymphoma, despite substantial improvements in survival, is usually incurable. Several randomized studies have shown that the combination of anti-CD20 and chemotherapy can improve overall survival for these patients. Recently, the old concept of maintenance treatment developed for acute leukemias was reintroduced in the treatment of indolent lymphomas. On the basis of its favorable toxicity profile, single agent rituximab remains a valuable option when given in a prolonged schedule to obtain durable remissions. A first remission is easily obtained but relapses appear unavoidable. Patients achieving a partial response have poorer outcomes compared with those achieving complete remission. Furthermore, it has been demonstrated that among patients with follicular lymphoma who reach complete remission, those obtaining negative minimal residual disease, as assessed by molecular biology, have a better outcome compared with those remaining with residual disease. There is, therefore, a rationale to give additional treatment in an attempt to eradicate or to control the lymphoma cells responsible for relapse. An ideal maintenance regimen would have limited toxicity and should be easy to administer. Results of the International Primary Rituximab and Maintenance study show that 2 years of rituximab maintenance prolongs progression free survival, delays the time to next antilymphoma treatment and improves the quality of response in patients with previously untreated follicular lymphoma. Rituximab maintenance was well tolerated with a limited number of adverse events.
- Retracted
- 25 May 2011
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (7) , 1401-1403
Rituximab–cyclophosphamide–dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia
We report our experience on rituximab–cyclophosphamide–dexamethasone (RCD) combination therapy for the treatment of autoimmune disorders in 48 patients with chronic lymphocytic leukemia (CLL). The diagnosis of autoimmune disease (AID) was autoimmune hemolytic anemia (AIHA) in 26 (54%), autoimmune thrombocytopenic purpura (AITP) in nine (18.8%), Evans syndrome in eight (16.7%), and pure red cell anemia (PRCA) in five patients (10.5%). CLL was considered progressive in 40% of subjects upon AID diagnosis. Overall, an 89.5% response rate was obtained with this combination, irrespective of the AID type. Relapse occurred in 19 patients (39.6%). The median duration of autoimmunity was 24 months, but the duration of response of autoimmunity (DR-AI) was higher for patients presenting with: (1) AID early during the CLL course (<3 years), or (2) both and pure red cell aplasia (PRCA) in five patients (10.5%) and AIHA.
- 25 May 2011
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (7) , 1401-1403
RetractedRituximab–cyclophosphamide–dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia
We report our experience on rituximab–cyclophosphamide–dexamethasone (RCD) combination therapy for the treatment of autoimmune disorders in 48 patients with chronic lymphocytic leukemia (CLL). The diagnosis of autoimmune disease (AID) was autoimmune hemolytic anemia (AIHA) in 26 (54%), autoimmune thrombocytopenic purpura (AITP) in nine (18.8%), Evans syndrome in eight (16.7%), and pure red cell anemia (PRCA) in five patients (10.5%). CLL was considered progressive in 40% of subjects upon AID diagnosis. Overall, an 89.5% response rate was obtained with this combination, irrespective of the AID type. Relapse occurred in 19 patients (39.6%). The median duration of autoimmunity was 24 months, but the duration of response of autoimmunity (DR-AI) was higher for patients presenting with: (1) AID early during the CLL course (<3 years), or (2) both and pure red cell aplasia (PRCA) in five patients (10.5%) and AIHA.
- 1 September 2010
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 22 (5) , 414-418
Role of early PET in the management of diffuse large B-cell lymphoma
This article reviews the role of interim fluorine-18-fluorodeoxyglucose (FDG)-PET in the management of aggressive non-Hodgkin lymphoma. In the diagnosis of diffuse large B-cell lymphoma, FDG-PET has proved to be a highly sensitive imaging modality. The specificity of 18FDG-PET is improved with the addition of computed tomography (CT) and combined PET/CT is now considered a standard staging procedure for aggressive lymphoma. In addition, residual FDG positivity at the end of therapy is strongly predictive for inferior survival and has been incorporated into revised response criteria for aggressive lymphoma. With the established prognostic value of PET/CT both before and after therapy, interest has now turned to whether interim FDG-PET could be an early indicator of tumor sensitivity. Current clinical trials are now focused on clarifying the role of PET/CT in the early distinction between good and poor responders to standard immunochemotherapy. The interest in such early patient selection assumes that a rapid metabolic response to standard immunochemotherapy predicts a better therapeutic response and survival, and that nonresponders may benefit from an early change in therapy. Preliminary data suggested that interim PET could identify the early presence of such residual disease. However, recent publications are hindered by important variances in patient populations and treatment protocols, the timing and methodology of scans, the reporting criteria used to assess response, and the reproducibility of reporting in accordance with these criteria. Questions remain on the utility of FDG-PET in this indication.
- 1 September 2010
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 22 (5) , 414-418
Role of early PET in the management of diffuse large B-cell lymphoma
This article reviews the role of interim fluorine-18-fluorodeoxyglucose (FDG)-PET in the management of aggressive non-Hodgkin lymphoma. In the diagnosis of diffuse large B-cell lymphoma, FDG-PET has proved to be a highly sensitive imaging modality. The specificity of 18FDG-PET is improved with the addition of computed tomography (CT) and combined PET/CT is now considered a standard staging procedure for aggressive lymphoma. In addition, residual FDG positivity at the end of therapy is strongly predictive for inferior survival and has been incorporated into revised response criteria for aggressive lymphoma. With the established prognostic value of PET/CT both before and after therapy, interest has now turned to whether interim FDG-PET could be an early indicator of tumor sensitivity. Current clinical trials are now focused on clarifying the role of PET/CT in the early distinction between good and poor responders to standard immunochemotherapy. The interest in such early patient selection assumes that a rapid metabolic response to standard immunochemotherapy predicts a better therapeutic response and survival, and that nonresponders may benefit from an early change in therapy. Preliminary data suggested that interim PET could identify the early presence of such residual disease. However, recent publications are hindered by important variances in patient populations and treatment protocols, the timing and methodology of scans, the reporting criteria used to assess response, and the reproducibility of reporting in accordance with these criteria. Questions remain on the utility of FDG-PET in this indication.
- 1 January 2009
- Published by Elsevier in Blood Reviews
- Vol. 23 (1) , 11-23
Recent developments in the treatment of aggressive non-Hodgkin lymphoma
- 1 January 2009
- Published by Elsevier in Blood Reviews
- Vol. 23 (1) , 11-23
Recent developments in the treatment of aggressive non-Hodgkin lymphoma